Cantargia
1.715
SEK
-7.25 %
CANTA
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
1,312 following
-7.25%
-5.35%
-50.97%
-61.96%
-54.12%
-55.78%
-89.04%
-89.61%
-75.73%
Cantargia is a pharmaceutical company. Today, there is specialization in the development of antibody drugs used in the treatment of leukemia and other cancers such as lung and pancreatic cancer. The company's objective is to develop, sell and license drug candidates to companies operating in the mentioned work area. The largest operations are in the Nordic market, with headquarters in Lund.
Read moreMarket cap
472.53M SEK
Turnover
2.48M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Financial calendar
21/2
2025
Annual report '24
13/5
2025
Interim report Q1'25
15/5
2025
General meeting '24
ShowingAll content types
Cantargia announces outcome of the rights issue
Cantargia publishes strong preclinical effects and clinical monotherapy results on nadunolimab in pancreatic cancer in Journal for Immunotherapy of Cancer
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools